conjugated-trastuzumab (Biocon/IATRICa)

N/A

Report date: 2025/04/21 17:03:47

Base Information

Drug Nameconjugated-trastuzumab (Biocon/IATRICa)
Drug Alias Nameimmunoconjugates (Biocon/IATRICa)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIATRICa Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIATRICa IncBiocon Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A